EGM to Re-propose CEO Compensation Limit of 800M Won and Amend Articles

Agenda item 1: Amendment of articles of incorporation to reflect revised Commercial Law (e.g., basis for self-share disposal, introduction of electronic voting, expansion of directors' duty of loyalty).
Conditional agenda: Establishment of Director Compensation Management Regulations: Version A if article amendment passes (linked to revised articles), Version B if fails (separate standard).
Re-proposal of CEO compensation limit of 800 million won: previously rejected at 28th regular meeting. Actual total director compensation in 2025 was 1.168 billion won; previous limit was 2 billion.
2025 turnaround: Separate revenue 11.3 billion won (recovery from 10.4 billion in 2024), operating loss reduced to 1.3 billion (vs. 9.4 billion loss in 2024), net loss to 1.8 billion (vs. 10.3 billion loss).
FDA 510(k) approval for OmniOx 750U model, expecting full-scale North American sales in 2026.
Consumables business high growth: sales volume from 10,000 units to over 30,000 (300% increase), accounting for 18% of total revenue.
Affiliate Mek Healthcare turned profitable: No.1 market share in sleep apnea devices.
Established local subsidiaries in India and Turkey; SKD operations in Mexico and India.
Director compensation rule: bonus cap at 10% of operating profit or 5% of sales; reduction/deferral possible in financial crisis.
Electronic voting and electronic proxy introduced (entrusted to Samsung Securities), period May 8-17, 2026.

ADVERTISEMENT (250px+)